Truist Securities Maintains Buy on Agios Pharmaceuticals, Raises Price Target to $41
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $36 to $41.
Truist Securities analyst Gregory Renza maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Buy and raises the price target from $36 to $41.